Cor/Schering Integrilin Revenue Recovery Projected After Label Change
Executive Summary
Cor Therapeutics expects Integrilin efficacy data and the co-promotional deal with Genentech will help the company recover from the recent inventory drawdown of the peptide glycoprotein IIb/IIIa receptor antagonist.
You may also be interested in...
Cor Integrilin Higher Dosing Data First Quarter FDA Filing Expected
Cor Therapeutics expects to file study data with FDA during the first quarter for a change in the Integrilin (eptifibatide) dosing regimen for patients undergoing coronary stent procedures.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials